Abstract
BACKGROUND: The oncologic safety of dental implants (DIs) in patients with oral field cancerization (OFC) remains uncertain. Increasing reports of oral squamous cell carcinoma (OSCC) developing adjacent to DIs have raised concerns regarding the interaction between implants, chronic inflammation, and genetically altered mucosa. METHODS: A comprehensive PubMed/MEDLINE search was performed through June 2025 to identify English- or Spanish-language publications reporting primary OSCC occurring in proximity to DIs. Extracted variables included patient demographics, tumor site, clinical presentation, presence of oral potentially malignant disorders (OPMD) or prior OSCC, peri-implant inflammation, management, and outcomes. Cases describing clinical features compatible with field-altered mucosa (e.g., OPMD or prior OSCC) were evaluated descriptively, recognizing that formal histopathologic or molecular evidence of OFC was rarely reported. RESULTS: A total of 105 implant-associated OSCC cases were identified. The mean patient age was 66.8 years (range: 40-90), with a female predominance (1.3:1). The mandible was the most frequently involved site (86.7%). A prior history of OPMD or OSCC was reported in 53 patients (50.5%), and peri-implantitis preceding diagnosis in 21 cases (19.0%). The most common clinical presentations were exophytic (59.0%) and ulcerated (37.1%) lesions, frequently mimicking peri-implantitis and contributing to diagnostic delay. Reported outcomes included recurrence in 11 cases (10.5%) and death in 13 cases (12.4%). CONCLUSIONS: Current evidence suggests that implant-associated OSCC frequently occurs in patients with pre-existing mucosal alterations and may be influenced by the interaction of field cancerization with local inflammatory and mechanical factors. Implant rehabilitation in individuals with OPMD, prior OSCC, or epithelial dysplasia should be undertaken cautiously, with rigorous long-term surveillance to ensure oncologic safety.